Saturday, December 16, 2017 9:03:58 AM
You realize that most of that is way outdated and has nothing to do with their subsidiary with orphan drug status for pediatric MS, nor their timing of having a non addictive pain killer ready to go when the public is most interested in a solution to opioid epidemic..
Not saying their aren’t gremlins here or that a bunch of sleazy salesman have tried in the past to make this succeed. Character is most definitely a consideration.
But they are a financing and clinical trial away from being very promising.
No pumping of piss poor financing will work any longer... it happens now or never..
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM